2 weeks Ago By ABMN Staff
Summit Investment Advisors Inc. raised its holdings in Scholar Rock Holding Co. ( NASDAQ:SRRK – Free Report ) by 16.
9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 8,109 shares of the company’s stock after acquiring an additional 1,170 shares during the quarter. Summit Investment Advisors Inc.
’s holdings in Scholar Rock were worth $350,000 as of its most recent SEC filing. Several other institutional investors have also added to or reduced their stakes in SRRK. GAMMA Investing LLC boosted its stake in Scholar Rock by 51.
8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after purchasing an additional 269 shares in the last quarter. Global Retirement Partners LLC raised its holdings in shares of Scholar Rock by 584.
7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after buying an additional 766 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Scholar Rock by 1,321.
8% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after buying an additional 1,031 shares during the period. Amalgamated Bank grew its holdings in shares of Scholar Rock by 30.
6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after buying an additional 620 shares during the last quarter. Finally, KBC Group NV acquired a new position in shares of Scholar Rock in the 4th quarter valued at $131,000.
Institutional investors and hedge funds own 91.08% of the company’s stock. Scholar Rock Price Performance NASDAQ:SRRK opened at $30.
71 on Monday. The firm’s fifty day moving average is $33.26 and its two-hundred day moving average is $35.
47. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of -13.
07 and a beta of 0.56. The company has a debt-to-equity ratio of 0.
63, a quick ratio of 3.88 and a current ratio of 3.88.
Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.
98. Insider Transactions at Scholar Rock Analysts Set New Price Targets Separately, Wedbush reiterated an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a research note on Tuesday, March 25th.
Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $42.67. Get Our Latest Report on Scholar Rock About Scholar Rock ( Free Report ) Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. Featured Articles Want to see what other hedge funds are holding SRRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Scholar Rock Holding Co.
( NASDAQ:SRRK – Free Report ). Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter .
.
